Lindane-containing lice treatments will undergo relabeling to warn of overuse, discuss alternatives.
Executive Summary
LINDANE PRODUCT LABELS WILL BE REVISED TO RECOMMEND SECOND-LINE USE ONLY in the treatment of lice. FDA is recommending lindane (gamma benzene hexachloride) use only for patients who have failed to respond to, or are intolerant of, other approved lice and scabies therapies that do not contain lindane. The FDA-prompted changes are in response to claims that lindane, an insecticide used in prescription-only pediculicides, might cause neurological damage in children.